Abstract
Silent information regulator 2 (Sir2) proteins, or sirtuins, are a family of proteins which influence several physiological responses and have implications for treating diseases of ageing. In this context, we have presented a summarized view on the discovery of Sir2 family proteins, the enzymatic activities, the role of sirtuins in aging, lifespan and onset of age-related symptoms. In addition, we have described the roles of mammalian sirtuins-with particular emphasis on their associations to aging, metabolism, and age related diseases with recent references. Current findings provide an understanding about mammalian sirtuins and their target diseases, small molecules discovery or drug discovery targeting sirtuin to tackle the serious diseases of aging.
Keywords: Aging, age related diseases, drug target, metabolism, sirtuins.
Current Drug Targets
Title:Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Volume: 14 Issue: 6
Author(s): Chiranjib Chakraborty and George Priya Doss. C
Affiliation:
Keywords: Aging, age related diseases, drug target, metabolism, sirtuins.
Abstract: Silent information regulator 2 (Sir2) proteins, or sirtuins, are a family of proteins which influence several physiological responses and have implications for treating diseases of ageing. In this context, we have presented a summarized view on the discovery of Sir2 family proteins, the enzymatic activities, the role of sirtuins in aging, lifespan and onset of age-related symptoms. In addition, we have described the roles of mammalian sirtuins-with particular emphasis on their associations to aging, metabolism, and age related diseases with recent references. Current findings provide an understanding about mammalian sirtuins and their target diseases, small molecules discovery or drug discovery targeting sirtuin to tackle the serious diseases of aging.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib and C George Priya Doss., Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060008
DOI https://dx.doi.org/10.2174/1389450111314060008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Left Ventricular Noncompaction: New Insights into a Poorly Understood Disease
Current Cardiology Reviews Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry The Insular Cortex and Takotsubo Cardiomyopathy
Current Pharmaceutical Design Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry